How To Use HCPCS Code C9469

HCPCS code C9469 describes the injection of triamcinolone acetonide, a preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg. This code is used to identify the specific procedure and medication administered by healthcare providers. In this article, we will explore the details of HCPCS code C9469, including its official description, procedure, when to use it, billing guidelines, historical information, Medicare and insurance coverage, and provide examples of when this code should be billed.

1. What is HCPCS C9469?

HCPCS code C9469 is used to identify the injection of triamcinolone acetonide, a preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg. This code is specific to this particular medication and dosage and should be used when reporting this procedure.

2. Official Description

The official description of HCPCS code C9469 is “Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg.” The short description for this code is “Enteral supp not otherwise c.”

3. Procedure

1. Prepare the injection site according to standard aseptic technique.
2. Draw up the prescribed dosage of triamcinolone acetonide into a syringe.
3. Administer the injection using the appropriate technique, ensuring proper needle placement and depth.
4. Monitor the patient for any immediate adverse reactions or complications.

4. When to use HCPCS code C9469

HCPCS code C9469 should be used when the healthcare provider administers an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg. It is important to ensure that the specific medication and dosage match the description provided by the code.

5. Billing Guidelines and Documentation Requirements

When billing for HCPCS code C9469, healthcare providers should ensure that the documentation supports the administration of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg. This may include the medication order, administration record, and any relevant clinical notes. The billing should be done according to the guidelines set by the payer, ensuring accurate coding and appropriate reimbursement.

6. Historical Information and Code Maintenance

HCPCS code C9469 was added to the Healthcare Common Procedure Coding System on January 01, 1985. It has an effective date of January 01, 1996. The code has a termination date of June 30, 2018, indicating that it is no longer in use. No maintenance actions have been taken for this code, as indicated by the action code N, which means no maintenance for this code.

7. Medicare and Insurance Coverage

Medicare and insurance coverage for HCPCS code C9469 may vary. The pricing indicator code for this code is 57, which indicates that it is priced by other carriers. The multiple pricing indicator code is A, which means it is not applicable as HCPCS priced under one methodology. It is important to check with the specific payer to determine coverage and reimbursement for this code.

8. Examples

Here are five examples of when HCPCS code C9469 should be billed:

1. A patient with a chronic inflammatory condition receives an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg to manage their symptoms.
2. A healthcare provider administers an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg to a patient with a localized joint inflammation.
3. A patient undergoing a specific procedure requires an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg to reduce post-operative inflammation.
4. A patient with a chronic skin condition receives an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg to manage their symptoms.
5. A healthcare provider administers an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, in a dosage of 1 mg to a patient with a specific allergic reaction.